



Intercell AG wins EUROPEAN BIOTECHNICA AWARD 2006

Vienna (Austria), October 13, 2006 – Intercell AG was honoured with the first prize in the final round of the **Biotechnica Award** 2006 during yesterday's ceremony at the Biotech CEO Conference in Zürich. The Biotechnica Award, endowed with 40,000 Euros, is awarded by the Deutsche Messe AG for the fourth time to European biotech and life science companies in the fields of biotechnology and related life sciences with proven success in launching innovative products or services, or in implementing promising new business concepts.

The jury including experts from science and industry as well as representatives of the capital markets, has selected three finalists from 16 outstanding candidates from eight countries in the first round. Alongside scientific innovation, the jury was judging criteria such as commercial viability, market relevance, marketing concepts and business models.

The prizes were presented by the German Federal Minister of Education and Research, Dr. Annette Schavan. The 2nd prize was awarded to Genmab S/A, a biotechnology company located in Denmark, and the 3rd prize was awarded to the German biotech company amaxa GmbH.

Conditions for Applicants:

- Market presence of at least two years
- At least 30 to 350 employees (maximum)
- Annual turnover of up to 50 million euros
- Independent business (maximum 25 percent share of company capital held by large company, except for venture-capital companies)
- Successful activities on the biotechnology/life sciences markets

For more information, please visit: www.biotechnica.de/award_e

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and S. aureus, which are in Phase I, and more than five other product candidates focused on infectious diseases in



pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.